Home pageDRREDDY • NSE
add
Dr. Reddy's Laboratories
Chiusura precedente
1232,20 ₹
Intervallo giornaliero
1204,00 ₹ - 1235,50 ₹
Intervallo annuale
1129,00 ₹ - 1379,70 ₹
Cap di mercato
1,02Â Bln INR
Volume medio
1,65Â Mln
Rapporto P/E
18,40
Dividendo/Prezzo
0,65%
Borsa valori principale
NSE
Notizie del mercato finanziario
Dati finanziari
Conto economico
Entrate
Utile netto
| (INR) | dic 2025info | Variazione Y/Y |
|---|---|---|
Entrate | 87,27Â Mld | 4,41% |
Spese di gestione | 32,48Â Mld | 7,03% |
Utile netto | 12,10Â Mld | -14,40% |
Margine di profitto netto | 13,86 | -18,04% |
Utili per azione | 14,77 | -12,79% |
EBITDA | 19,54Â Mld | -16,58% |
Aliquota fiscale effettiva | 22,90% | — |
Stato patrimoniale
Totale attivo
Totale passivo
| (INR) | dic 2025info | Variazione Y/Y |
|---|---|---|
Investimenti cash/breve termine | 82,59Â Mld | 37,83% |
Totale attivo | 562,90Â Mld | 17,01% |
Totale passivo | 187,14Â Mld | 17,34% |
Patrimonio netto totale | 375,76 Mld | — |
Azioni in circolazione | 832,57 Mln | — |
Prezzo/valore contabile | 2,76 | — |
Rendimento delle attività | 6,48% | — |
Rendimento sul capitale | 8,29% | — |
Flusso di cassa
Flusso di cassa netto
| (INR) | dic 2025info | Variazione Y/Y |
|---|---|---|
Utile netto | 12,10Â Mld | -14,40% |
Liquidità di esercizio | 10,91 Mld | 64,77% |
Liquidità da investimenti | -10,29 Mld | -88,57% |
Liquidità da finanziamenti | 7,78 Mld | 1.218,14% |
Flusso di cassa netto | 8,75Â Mld | 400,92% |
Flusso di cassa libero | -672,75Â Mln | -26,52% |
Informazioni
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
CEO
Fondazione
1984
Sito web
Dipendenti
27.811